Home / Stocks / TMDX

TransMedics Group (TMDX, Medical devices) Stock Valuation & Fair Value

Mixed on our tests

TransMedics Group (TMDX, Medical devices) trades at a current P/E of 42.2, about 3% below its historical normal valuation, with a forward growth estimate of 20.2% and a PEG of 2.09. Analysts' one-year estimates have been hit 33% of the time. Priced at its historical normal P/E of 43.4 on the same blended earnings, the 2026-11-06 close of $88.24 corresponds to about $90.60 a share. This is a valuation reference, not a price target.

How to read these numbers: the PEG ratio and current P/E versus normal P/E.

DATA AS OF 2026-11-07
Current P/E
42.2
Normal P/E
43.4
PEG
2.09
Fwd growth
20.2%
Div yield
0.0%
RSI (14)
66.6
Neutral
Technical context
  • Price $88.24 at the Nov 6 close, 22.0% above the 20-day average ($72.30) and 10.8% above the 50-day ($79.61).
  • RSI (14) at 66.6.
  • 52-week range $62.04 to $150.42: the price is 41.3% below the high and 42.2% above the low.

The Street vs SeerForecast

Wall Street's mean price target for TMDX is $98.73 across 11 analysts, 11.9% above the current price. The average analyst rating is Buy. Our SeerForecast read of the same stock, formed without analyst targets: mixed on our tests. When the two disagree, start your digging there.

Valuation flags

Verdict history

tickerseer's rating moved from weak on forward returns (2026-07-31) to mixed on our tests (2026-11-02). New rating rules took effect in the week of 2026-11-02, and this rating moved across that change, so part of the move may come from the new rules rather than the company.

Current P/E and rating by weekCurrent P/E moved from 24.5 to 31.6 between 2026-07-31 and 2026-10-30, against a normal P/E of 43.4, with 3 rating changes over 14 recorded weeks.2026-07-31: P/E 24.5, Weak on forward returns, recalculated for the week of 2026-07-312026-07-31: P/E 24.7, Weak on forward returns, recorded live 2026-08-032026-08-07: P/E 24.7, Weak on forward returns, recalculated for the week of 2026-08-072026-08-07: P/E 28.9, Poor on forward returns, recorded live 2026-08-102026-08-14: P/E 28.9, Poor on forward returns, recalculated for the week of 2026-08-142026-08-14: P/E 31.5, Poor on forward returns, recorded live 2026-08-172026-08-21: P/E 31.5, Poor on forward returns, recalculated for the week of 2026-08-212026-08-21: P/E 34.5, Poor on forward returns, recorded live 2026-08-242026-08-27: P/E 34.5, Poor on forward returns, recalculated for the week of 2026-08-272026-08-28: P/E 34.5, Poor on forward returns, recalculated for the week of 2026-08-282026-08-28: P/E 34.5, Poor on forward returns, recalculated for the week of 2026-08-302026-08-28: P/E 32.9, Poor on forward returns, recorded live 2026-08-312026-09-04: P/E 32.9, Poor on forward returns, recalculated for the week of 2026-09-052026-09-04: P/E 34.3, Poor on forward returns, recorded live 2026-09-072026-09-11: P/E 34.3, Poor on forward returns, recalculated for the week of 2026-09-122026-09-11: P/E 32.3, Poor on forward returns, recorded live 2026-09-142026-09-18: P/E 32.3, Poor on forward returns, recalculated for the week of 2026-09-192026-09-18: P/E 34.8, Poor on forward returns, recorded live 2026-09-212026-09-25: P/E 34.8, Poor on forward returns, recalculated for the week of 2026-09-262026-09-25: P/E 35.4, Poor on forward returns, recorded live 2026-09-282026-10-02: P/E 35.4, Poor on forward returns, recalculated for the week of 2026-10-032026-10-02: P/E 34.1, Poor on forward returns, recorded live 2026-10-052026-10-09: P/E 34.1, Poor on forward returns, recalculated for the week of 2026-10-102026-10-09: P/E 34.1, Poor on forward returns, recorded live 2026-10-122026-10-16: P/E 34.1, Poor on forward returns, recalculated for the week of 2026-10-172026-10-16: P/E 31.9, Poor on forward returns, recorded live 2026-10-192026-10-23: P/E 32.9, Weak on forward returns, recorded live 2026-10-262026-10-30: P/E 32.9, Mixed on our tests, recalculated for the week of 2026-10-312026-10-30: P/E 31.6, Mixed on our tests, recorded live 2026-11-0225.030.035.040.0Jul 31Aug 23Sep 15Oct 7Oct 30Normal P/E 43.4
Mixed on our testsWeak on forward returnsPoor on forward returnsLarger dot: a stronger reading

Not every point was recorded live. Points marked recalculated are worked out from the metrics tickerseer archived that week.

Selected weeks: the first, the latest, every week the rating moved, and the cheapest and dearest.

WeekCurrent P/EPremium to normal P/ERating
2026-07-31P/E 24.5-44%Weak on forward returns (recalculated)
2026-08-10P/E 28.9-33%Poor on forward returns
2026-09-28P/E 35.4-18%Poor on forward returns
2026-10-26P/E 32.9-24%Weak on forward returns
2026-10-31P/E 32.9-24%Mixed on our tests (recalculated) (across a rating rules change)
2026-11-02P/E 31.6-27%Mixed on our tests ← now
Show all 29 readings
WeekCurrent P/EPremium to normal P/ERating
2026-07-31P/E 24.5-44%Weak on forward returns (recalculated)
2026-08-03P/E 24.7-43%Weak on forward returns
2026-08-07P/E 24.7-43%Weak on forward returns (recalculated)
2026-08-10P/E 28.9-33%Poor on forward returns
2026-08-14P/E 28.9-33%Poor on forward returns (recalculated)
2026-08-17P/E 31.5-27%Poor on forward returns
2026-08-21P/E 31.5-27%Poor on forward returns (recalculated)
2026-08-24P/E 34.5-21%Poor on forward returns
2026-08-27P/E 34.5-21%Poor on forward returns (recalculated)
2026-08-28P/E 34.5-21%Poor on forward returns (recalculated)
2026-08-30P/E 34.5-21%Poor on forward returns (recalculated)
2026-08-31P/E 32.9-24%Poor on forward returns
2026-09-05P/E 32.9-24%Poor on forward returns (recalculated)
2026-09-07P/E 34.3-21%Poor on forward returns
2026-09-12P/E 34.3-21%Poor on forward returns (recalculated)
2026-09-14P/E 32.3-26%Poor on forward returns
2026-09-19P/E 32.3-26%Poor on forward returns (recalculated)
2026-09-21P/E 34.8-20%Poor on forward returns
2026-09-26P/E 34.8-20%Poor on forward returns (recalculated)
2026-09-28P/E 35.4-18%Poor on forward returns
2026-10-03P/E 35.4-18%Poor on forward returns (recalculated)
2026-10-05P/E 34.1-21%Poor on forward returns
2026-10-10P/E 34.1-21%Poor on forward returns (recalculated)
2026-10-12P/E 34.1-21%Poor on forward returns
2026-10-17P/E 34.1-21%Poor on forward returns (recalculated)
2026-10-19P/E 31.9-26%Poor on forward returns
2026-10-26P/E 32.9-24%Weak on forward returns
2026-10-31P/E 32.9-24%Mixed on our tests (recalculated) (across a rating rules change)
2026-11-02P/E 31.6-27%Mixed on our tests ← now

Frequently asked questions

Is TransMedics Group stock overvalued?

At a current P/E of 42.2 versus its historical normal P/E of 43.4, TransMedics Group trades about 3% below its typical valuation, with a PEG of 2.09 on 20.2% forward growth. tickerseer currently rates it mixed on our tests.

What is TransMedics Group's fair value and PEG?

TransMedics Group trades at a current P/E of 42.2 against a historical normal P/E of 43.4, a PEG of 2.09, and a forward growth estimate of 20.2%. Priced at its historical normal P/E of 43.4 on the same blended earnings, the 2026-11-06 close of $88.24 corresponds to about $90.60 a share. This is a valuation reference, not a price target.

Has tickerseer's rating of TransMedics Group changed?

tickerseer's rating moved from weak on forward returns (2026-07-31) to mixed on our tests (2026-11-02). New rating rules took effect in the week of 2026-11-02, and this rating moved across that change, so part of the move may come from the new rules rather than the company.

What is the analyst price target for TransMedics Group?

The mean Wall Street price target for TransMedics Group is $98.73 across 11 analysts, 11.9% above the current price. tickerseer's SeerForecast verdict is formed independently of analyst targets.

Industry: Medical devices. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and an AI research note where we have one. Options setups and metric history are part of the paid plans.

See the full analysis →🔔 Track TMDX free: valuation & earnings alerts

Get the free weekly earnings preview

One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.

It's free, and you can unsubscribe any time. We also send a short product update once a month. Educational content, not investment advice.